BICX.OIDBiocorrx INC
10-Q: BioCorRx Reports Q3 2025 Results, Lucemyra Boosts Revenue
Sentiment:
Quarterly Report
BioCorRx Inc. reported a significant revenue increase in Q3 2025, driven by the Lucemyra acquisition, despite ongoing net losses and a substantial working capital deficit, raising going concern doubts.
Capital raiseThe company intends to raise additional capital through private placements of debt and equity securities.During the nine months ended September 30, 2025, the company received $942,700 from related party promissory notes.On July 29, 2025, the company entered into a Securities Purchase Agreement (SPA) with accredited investors for the sale of 2,000,000 shares of common stock and accompanying warrants for total gross proceeds of $700,000.On September 29, 2025, the second tranche of the SPA was completed, raising an additional $350,000.Subsequent to September 30, 2025, on October 21, 2025, Louis Lucido, President and Director, entered into a Subscription Agreement to purchase 2,908,573 shares of Common Stock and a warrant for $1,018,000.
Worse than expectedThe company explicitly states 'These conditions raise substantial doubt about the Company's ability to continue as a going concern for the next twelve-month period since the date of the financial statements were issued.'Despite a decrease in net loss, the net loss attributable to BioCorRx Inc. increased slightly, and the accumulated deficit grew to over $87 million.Working capital deficit significantly worsened to $(13,575,951) from $(12,120,420) at the end of the prior fiscal year, indicating deteriorating short-term liquidity.Net cash used in operating activities increased, showing a higher cash burn rate.Material weaknesses in internal controls over financial reporting were identified, which is a negative indicator for operational efficiency and financial reliability.
Summary
- Net revenues for the nine months ended September 30, 2025, increased significantly to $948,362, up from $7,665 in the prior year, primarily due to Lucemyra distribution sales.
- The company reported a net loss of $3,037,545 for the nine months ended September 30, 2025, an improvement from a net loss of $3,984,469 in the same period last year.
- Net loss attributable to BioCorRx Inc. for the nine months ended September 30, 2025, was $(3,992,701), a slight increase from $(3,941,509) in the prior year.
- Cash and cash equivalents stood at $287,688 as of September 30, 2025, an increase from $88,033 at December 31, 2024.
- Working capital deficit was $(13,575,951) as of September 30, 2025.
- The accumulated deficit reached $(87,201,843) as of September 30, 2025.
- Operating expenses increased to $5,245,819 for the nine months ended September 30, 2025, from $4,005,430 in the prior year, driven by higher R&D and SG&A costs.
- Grant income increased to $1,435,379 for the nine months ended September 30, 2025, compared to $1,204,407 in the prior year, primarily from a new NIDA grant for methamphetamine use disorder studies.
- The company acquired certain assets and liabilities related to Lucemyra, an FDA-approved prescription medication for opioid withdrawal, on March 4, 2025, which contributed to the revenue increase.
- A civil complaint filed under the federal False Claims Act against the company was dismissed without prejudice on September 2, 2025.
- The company settled litigation with Pellecome for $418,000, with $198,000 remaining outstanding as of September 30, 2025.
Sentiment
Score: 3
Explanation: While revenue growth from the Lucemyra acquisition and increased grant income are positive, the company's severe liquidity issues, substantial accumulated deficit, and explicit 'going concern' warning, coupled with identified material weaknesses in internal controls, indicate a highly precarious financial position. The capital raises are critical for survival but also dilute existing shareholders.
Positives
- Net revenues for the nine months ended September 30, 2025, increased significantly to $948,362 from $7,665 in the prior year, primarily due to the acquisition and distribution sales of Lucemyra.
- The net loss for the nine months ended September 30, 2025, decreased to $3,037,545 from $3,984,469 in the comparable prior year period.
- Grant income increased to $1,435,379 for the nine months ended September 30, 2025, from $1,204,407 in the prior year, supported by a new NIDA grant for BICX104 research.
- Cash and cash equivalents increased to $287,688 as of September 30, 2025, from $88,033 at December 31, 2024.
- The False Claims Act civil complaint against the company was dismissed without prejudice on September 2, 2025, resolving a potential legal liability.
Negatives
- The company continues to incur net losses and has an accumulated deficit of $(87,201,843) as of September 30, 2025.
- A substantial working capital deficit of $(13,575,951) as of September 30, 2025, indicates significant short-term liquidity challenges.
- Net cash used in operating activities increased to $(1,450,569) for the nine months ended September 30, 2025, from $(849,084) in the prior year, indicating higher cash burn.
- Total operating expenses increased by $921,090 for the three months ended September 30, 2025, and by $1,240,389 for the nine months ended September 30, 2025, compared to the prior year periods.
- The company has identified material weaknesses in its internal control over financial reporting, including undocumented policies, insufficient GAAP experience for complex transactions, and inadequate staff for segregation of duties.
- A significant portion of revenues (64% for Q3 2025) and accounts receivable (95% as of Sep 30, 2025) are concentrated with one customer, posing a concentration risk.
- The company still owes $198,000 on the Pellecome litigation settlement as of September 30, 2025.
Risks
- The company's ability to continue as a going concern is in substantial doubt due to recurring net losses and a significant working capital deficit.
- Reliance on raising additional capital through private placements of debt and equity securities, with no assurance that these funds will be available on acceptable terms or be sufficient to sustain operations.
- High customer concentration, with one customer accounting for 64% of Q3 2025 revenues and 95% of accounts receivable, poses a significant business risk.
- Material weaknesses in internal control over financial reporting could lead to financial misstatements or operational inefficiencies.
- Ongoing research and development activities for BICX104 are subject to the terms and conditions of government grants, including satisfactory progress and fund availability, and may not lead to regulatory approval or commercial success.
- The company is exposed to interest rate risks on its various promissory notes, some of which have increased interest rates due to default.
Future Outlook
The company intends to raise additional capital through private placements of debt and equity securities, strategic partnerships, and non-dilutive funding opportunities to address its liquidity challenges and fund development activities. Management continues to implement measures to reduce operating costs. Research and development for BICX104, a sustained release naltrexone implant for methamphetamine use disorder, is ongoing with NIDA grant funding for three years.
Management Comments
- Management believes that current cash on hand will not be sufficient to fund projected operating requirements for the next twelve months.
- Management continues to evaluate various financing options, including private placements of equity and convertible debt, strategic partnerships, and potential non-dilutive funding opportunities.
- Management continues to implement measures to reduce operating costs until sufficient capital is secured.
- The Chief Executive Officer and Chief Financial Officer concluded that financial statements and other financial information included in this quarterly report fairly present in all material respects the financial condition, results of operations, and cash flows.
Industry Context
BioCorRx operates in the addiction treatment and weight loss management sectors, with a focus on medication-assisted treatment (MAT) and drug development. The acquisition of Lucemyra, an FDA-approved opioid withdrawal medication, positions the company to generate immediate revenue in a critical public health area. Its R&D efforts for naltrexone implants align with broader industry trends towards long-acting, non-addictive treatments for substance use disorders, particularly for opioid and methamphetamine use, which are significant public health challenges. The company's reliance on government grants for R&D is common for early-stage drug developers, but commercialization success will depend on regulatory approvals and market adoption.
Comparison to Industry Standards
- NA The filing does not provide specific comparisons to industry benchmarks or competitor performance. The company's financial position, characterized by recurring losses and a significant accumulated deficit, suggests it is not currently performing at par with established, profitable industry leaders in the pharmaceutical or addiction treatment sectors.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors Member | NA | Katy DeVarney | 2025-03-04 | Appointment to the board. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Weaknesses | Identified material weaknesses in internal control over financial reporting, including inadequately documented policies and procedures, insufficient GAAP experience for complex transactions, and insufficient staff for optimal segregation of duties. | 2025-09-30 | These weaknesses are reasonably likely to adversely affect the company's ability to record, process, summarize, and report financial information reliably. |
Legal Proceedings
- The company settled litigation with Pellecome for $418,000 on March 11, 2025, with $198,000 remaining outstanding as of September 30, 2025. This stemmed from a judgment for costs and attorneys' fees totaling $332,503 plus $94,816 in accrued interest.
- A civil complaint filed under the federal False Claims Act (qui tam provisions) in the Western District of Washington was dismissed without prejudice on September 2, 2025. The complaint alleged violations of NIH/NIDA grant terms regarding research overhead, accounting entries, and project scope changes.
Related Party Transactions
- The company had advances from Kent Emry (Chairman) totaling $1,500 as of September 30, 2025.
- Advances from Louis C Lucido (Board Member) were $0 as of September 30, 2025, following several exchange agreements converting debt into common stock.
- Advances from Lourdes Felix (CEO and CFO) totaled $325,950 as of September 30, 2025.
- Promissory notes payable to Kent Emry totaled $663,610 as of September 30, 2025.
- Royalty agreements exist with Louis and Carolyn Lucido CRT LLC and J and R Galligan Revocable Trust, managed by related parties, involving payments from gross revenue of weight loss treatments.
Stakeholder Impact
- **Shareholders**: Significant dilution from ongoing equity raises and conversions of debt into common stock. The 'going concern' warning poses a substantial risk to investment value. The increase in net loss attributable to BioCorRx Inc. also negatively impacts per-share metrics.
- **Employees**: The company's precarious financial position and internal control weaknesses could create job insecurity or operational instability.
- **Customers**: The acquisition of Lucemyra and ongoing development of addiction treatments could benefit patients by expanding treatment options. However, the company's financial instability could impact long-term product availability or support.
- **Creditors**: Promissory notes have been subject to multiple amendments and defaults, indicating repayment risk. The settlement of the Pellecome litigation reduces one liability but leaves an outstanding balance.
- **Regulatory Authorities (FDA, NIH/NIDA)**: Continued R&D and grant funding demonstrate engagement, but compliance with grant terms and regulatory processes is critical. The dismissed False Claims Act complaint highlights past scrutiny.
Next Steps
- Raise additional capital through private placements of debt and equity securities, strategic partnerships, and non-dilutive funding opportunities.
- Continue research and development of BICX104 for opioid and methamphetamine use disorder, supported by NIDA grants.
- Implement measures to reduce operating costs.
- Address identified material weaknesses in internal control over financial reporting, including documenting policies and procedures, enhancing GAAP expertise, and improving segregation of duties.
- Continue to make payments on the Pellecome litigation settlement, with $198,000 remaining outstanding.
Key Dates
| Date | Description |
|---|---|
| 2013-01-22 | Company issued an unsecured promissory note payable to Kent Emry for $200,000. |
| 2015-12-10 | Company entered into a royalty agreement with Alpine Creek Capital Partners LLC. |
| 2016-07-28 | BioCorRx Inc. formed BioCorRx Pharmaceuticals, Inc., retaining 75.8% ownership. |
| 2018-02-12 | FDA deemed the 505(b)(2) pathway acceptable for BICX102 approval. |
| 2019-01-17 | Company received a Notice of Award from NIH for a grant supporting BICX102/BICX104. |
| 2019-05-24 | Company entered into a Master Services Agreement with Charles River Laboratories, Inc. for studies on BICX102/BICX104. |
| 2019-09-30 | Company entered into a Conversion Agreement with BICX Holding Company LLC for conversion of a $4,160,000 promissory note into common stock. |
| 2019-10-01 | The UnCraveRx Weight Loss Management Program officially launched. |
| 2020-10-31 | Company entered into a management services agreement with Joseph DeSanto MD, Inc. |
| 2021-05-07 | U.S. FDA cleared the Company's Investigational New Drug Application (IND) for its implantable naltrexone (BICX104) candidate. |
| 2021-07-01 | Company dismissed litigation against Pellecome without prejudice. |
| 2021-08-27 | Company received a Notice of Award from National Institute on Drug Abuse for BICX104 (UH3 grant). |
| 2021-09-09 | Company issued an unsecured promissory note payable to Kent Emry for $500,000. |
| 2021-10-06 | Date from which interest is accruing on the Pellecome judgment. |
| 2022-01-11 | Company entered into a Master Clinical Trial Agreement with Orange County Research Center for Phase 1 clinical trial with BICX104. |
| 2022-03-30 | Court entered judgment in favor of Pellecome for $235,886 in costs and attorneys' fees. |
| 2022-06-08 | Company issued a warrant to Kent Emry to purchase 119,617 common shares due to loan default. |
| 2022-10-06 | Company issued an unsecured promissory note payable to a third party for $100,000. |
| 2023-01-25 | Company issued an unsecured promissory note payable to a third party for $50,000. |
| 2023-02-02 | Company filed a motion requesting the California Superior Court for Orange County reverse its prior ruling regarding Pellecome. |
| 2023-09-06 | Company issued an unsecured promissory note payable to a third party for $150,000. |
| 2023-10-04 | Court of Appeal of the State of California upheld the March 30, 2022 judgment in favor of Pellecome. |
| 2023-11-09 | Company entered into Subscription Agreements with J and R Galligan Revocable Trust and Louis C Lucido. |
| 2023-11-10 | Company issued an unsecured promissory note payable to a third party for $200,000 cash proceeds. |
| 2023-12-08 | Company issued an unsecured promissory note payable to a third party for $200,000 cash proceeds. |
| 2024-01-05 | California Superior Court for Orange County entered an amended judgment of $332,503 in favor of Pellecome, plus $94,816 accrued interest. Louis Lucido appointed Interim President. |
| 2024-02-01 | Louis Lucido transitioned to President. |
| 2024-03-01 | BioCorRx Pharmaceuticals Inc. was awarded a grant of $11,029,977 from NIDA for BICX104 research for methamphetamine use disorder. |
| 2024-03-08 | Company entered into an amendment agreement to a promissory note originally issued on November 10, 2023. |
| 2024-03-14 | Company issued an unsecured promissory note payable to a third party for $200,000 cash proceeds. |
| 2024-03-25 | Company entered into an amendment agreement to a promissory note originally issued on December 8, 2023. |
| 2024-04-09 | Company and landlord agreed to move to a larger office space and extended lease term to April 30, 2029. |
| 2024-04-24 | Company entered into an Exchange Agreement with Mr. Lucido to convert promissory notes, advances, and director fees into common stock. |
| 2024-07-11 | Company entered into amendment agreements to promissory notes originally issued on March 14, 2024, and November 10, 2023. |
| 2024-08-23 | Company entered into a second amendment agreement to a promissory note originally issued on December 8, 2023. |
| 2024-10-07 | Company entered into an amendment agreement to a promissory note originally issued on September 6, 2023. |
| 2024-10-14 | Company entered into amendment agreements to promissory notes originally issued on March 14, 2024, and November 10, 2023, and an Exchange Agreement with Mr. Lucido. |
| 2024-11-13 | Company entered into an amendment agreement to a promissory note originally issued on January 25, 2023. |
| 2024-11-29 | Company entered into a third amendment agreement to a promissory note originally issued on December 8, 2023. |
| 2024-12-31 | Company entered into third and fourth amendment agreements to promissory notes originally issued on March 14, 2024, and November 10, 2023, and December 8, 2023. |
| 2025-01-21 | Company entered into an Exchange Agreement with Mr. Lucido to convert a $725,000 promissory note into common stock. |
| 2025-01-31 | Company entered into a fourth amendment agreement to a promissory note originally issued on December 8, 2023. |
| 2025-02-06 | Company entered into a second amendment agreement to a promissory note originally issued on September 6, 2023. |
| 2025-02-13 | Third parties exercised warrants on a cashless basis, resulting in the issuance of 117,241 shares of common stock. |
| 2025-02-28 | Company entered into fourth and fifth amendment agreements to promissory notes originally issued on March 14, 2024, and November 10, 2023. |
| 2025-03-04 | Company and BioCorRx Pharmaceuticals, Inc. entered into an Asset Purchase Agreement with USWM, LLC for Lucemyra assets. Katy DeVarney appointed to the board of directors. |
| 2025-03-07 | Company entered into a Repayment Agreement with a third party to exchange service fees for common stock. |
| 2025-03-11 | Company entered into a settlement agreement with Pellecome for $418,000. |
| 2025-03-31 | Company entered into an Exchange Agreement with Mr. Lucido to convert a $200,000 promissory note into common stock. |
| 2025-04-07 | Company entered into a fifth amendment agreement to a promissory note originally issued on December 8, 2023. |
| 2025-07-18 | Company entered into an Exchange Agreement with Mr. Lucido to convert a $212,500 promissory note into common stock, clearing his outstanding debt. |
| 2025-07-29 | Company entered into a Securities Purchase Agreement with accredited investors for the sale of 2,000,000 shares of common stock and warrants for $700,000. |
| 2025-08-28 | Plaintiff filed a motion to dismiss without prejudice the civil complaint in the Western District of Washington. |
| 2025-09-02 | Court granted the motion to dismiss the civil complaint. |
| 2025-09-29 | Purchasers completed the Second Tranche of the Securities Purchase Agreement, acquiring 1,000,000 shares and warrants for $350,000. |
| 2025-10-01 | Notice of acceleration of debt sent by Mr. Kent Emry for a promissory note of $1,018,493.15. |
| 2025-10-21 | Company entered into an Exchange Agreement with a holder of an outstanding promissory note, converting $182,819 into 522,341 shares and a warrant. Louis Lucido entered into a Subscription Agreement to purchase 2,908,573 shares and a warrant for $1,018,000. |
| 2025-10-24 | Full repayment of $1,018,493.15 to Mr. Kent Emry, satisfying the promissory note. |
| 2025-11-08 | There were 23,685,343 shares of registrant's common stock outstanding. |
| 2025-11-14 | Date of filing of the Quarterly Report on Form 10-Q. |
Recommendation
strong sellThe company explicitly states 'substantial doubt about the Company's ability to continue as a going concern.' This, combined with a massive accumulated deficit, a worsening working capital deficit, and increasing cash burn from operations, paints a dire financial picture. While revenue growth from the Lucemyra acquisition and increased grant income are positive, they are insufficient to offset the fundamental liquidity and solvency issues. The continuous reliance on dilutive capital raises and debt conversions, along with identified material weaknesses in internal controls, indicates severe operational and financial instability. A seasoned investor would view the 'going concern' warning as a critical red flag, suggesting a high risk of further value erosion or potential bankruptcy.
Keywords
BioCorRx, SEC Filing, 10-Q, Quarterly Report, Financial Results, Addiction Treatment, Naltrexone, BICX104, Opioid Use Disorder, Methamphetamine Use Disorder, Lucemyra, FDA Approval, Clinical Trials, Pharmaceuticals, Biotechnology, Going Concern, Capital Raise, Grant Funding, Working Capital Deficit, Corporate Governance, Legal Proceedings
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.